Copenhagen, Denmark, September 9, 2019 Genmab and Tempus sign agreement to research and develop novel targets Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a privately-owned technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.?The multi-year collaboration will combine Tempus? sequencing capabilities and industry-leading platform of integrated clinical and molecular data with Genmab?s state-of-the-art translational, biomarker and target discovery expertise. The companies will work together, based upon novel insights identified by Genmab, to advance new disease targets and biomarkers that may have the potential to generate new treatments in oncology. This new strategic collaboration builds upon existing service agreements between the companies. Under the terms of the collaboration agreement, the companies will jointly work on research projects that are identified by Genmab to explore novel product concepts and biomarkers. For any resulting products, Genmab will lead all development and commercial activities. Tempus will be eligible for undisclosed milestones and royalties from Genmab and will also have the option to fund part of product development programs in exchange for increased royalty payments due to Tempus under the agreement. ?Tempus has built the world?s largest library of clinical and molecular data, is a leader in the field of personalized medicine and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers,? said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Today?s news does not impact Genmab?s 2019 Financial Guidance. About Genmab? Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX^??(daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra^??(ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody^??platform for generation of bispecific antibodies, the HexaBody^?platform, which creates effector function enhanced antibodies, the HexElect^??platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody^??platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S. Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E:?mmp@genmab.com For Investor Relations:? Andrew Carlsen, Senior Director, Investor Relations T: +45 3377 9558; E:?acn@genmab.com This Media Release contains forward looking statements. The words ?believe?, ?expect?, ?anticipate?, ?intend? and ?plan? and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab?s most recent financial reports, which are available on?www.genmab.comand the risk factors included in Genmab?s final prospectus for our U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at?www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^?; the Y-shaped Genmab logo^?; Genmab in combination with the Y-shaped Genmab logo^?; HuMax^?; DuoBody^?; DuoBody in combination with the DuoBody logo^?; HexaBody^?; HexaBody in combination with the HexaBody logo^?; DuoHexaBody^?; HexElect^?; and UniBody^?. Arzerra^??is a trademark of Novartis AG or its affiliates. DARZALEX^??is a trademark of Janssen Pharmaceutica NV. Media Release?no. 12 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Kalvebod Brygge 43 1560 Copenhagen V Denmark

Attachment

• 190909_i12_Tempus